Crenezumab
Crenezumab (MABT 5102A; RG 7412) is a fully humanized anti-Aβ monoclonal antibody that binds multiple forms of Aβ, such as soluble, oligomeric and fibrillar, for use in Alzheimer's disease research[1].
Product Specifications
CAS Number
1095207-05-8
Product Name Alternative
MABT 5102A; RG 7412
UNSPSC
12352203
Target
Amyloid-β
Type
Inhibitory Antibodies
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/crenezumab.html
Purity
99.86
Solubility
10 mM in DMSO
Smiles
[Crenezumab]
Molecular Weight
(143.32 kDa)
References & Citations
[1]S Zampar, et al. N-terminal heterogeneity of parenchymal and vascular amyloid-β deposits in Alzheimer's disease. Neuropathol Appl Neurobiol. 2020 Dec;46 (7) :673-685.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400034-100 1x 100 µL
Cytokeratin 8/18 (C-51), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC401081-500 1x 500 µL
CD45RO (190-2F2.5), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC811224-100 1x 100 µL
HCG-beta (HCGb/54+ HCGb/459), CF680R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC882029-500 1x 500 µL
ARF1 (Golgi Apparatus Marker) (3F1), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC882368-500 1x 500 µL
Cytokeratin 6A (KRT6A) (Basal Cell Marker) (KRT6A/2368), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details